R educed upper limb function is common after stroke and is an adverse prognostic indicator for subjective wellbeing. [1] [2] [3] Poor upper limb function is associated with pain, particularly at the shoulder, which is reported by Ͼ50% of patients during the first 6 months after stroke. 4, 5 Surface neuromuscular electrical stimulation (sNMES) has been recommended as a safe method to improve upper limb outcomes after stroke. 6, 7 Proposed mechanisms include stimulation of the somatosensory cortex by augmented sensory feedback, and increased proprioceptive stimulation as a result of muscle activation. 8 Repetitive movements induced by sNMES may be important for motor re-learning. 9, 10 Other potential benefits include: increased muscle strength, improved joint alignment, reduced spasticity, and modification of visuospatial deficits. sNMES of cutaneous sensory nerves may separately modulate pain via gating pathways and central neuromodulation. 11 It is unclear whether this translates into functional benefit. 7, 12 Many previous randomized controlled trials of upper limb sNMES were small and of variable methodological quality. [13] [14] [15] [16] A systematic review identified the need for further research. 6 We undertook a randomized controlled trial to evaluate sNMES to the shoulder after acute stroke. Participants received a 4-week program of sNMES to the shoulder or placebo. Upper limb function, impairment, pain, disability, and global health status were compared between treatment groups at the end of the intervention period and 3 months after stroke.
Methods

Participants
Patients admitted to 2 neighboring stroke units were eligible if they had a new upper limb problem caused by stroke within the previous 10 days. Those with a previous upper limb problem, a cognitive/ language impairment likely to influence assessments, another diagnosis likely to interfere with rehabilitation, or a contraindication to sNMES were excluded. 26 and dependency at 7 days (Barthel ADL Index). 27 Participants were randomized by a central independent telephone computerized service and stratified according to severity of upper limb weakness (Frenchay Arm Test 20 score 0, 1 versus 2 to 5).
Intervention
Participants in the intervention group received a 4-week program of sNMES to the shoulder (1 hour, 3 times daily) via surface electrodes over supraspinatus and posterior deltoid. The basic stimulation frequency was 30 Hz. The stimulator on and off time was 15 seconds with a ramp up-and-down time of 3 seconds. The level of stimulation was increased until a comfortable gross muscle contraction was visible. Participants in the control group were given a "sham" stimulator, identical to the intervention, but an internal disconnection prevented any current from being delivered. The sNMES treatment regime and placement of electrodes was undertaken by a single researcher. Compliance was monitored using a diary.
Outcome Assessments
The primary outcome measure was upper limb function (ARAT) 21 3 months after stroke. Secondary outcome measures were undertaken at the end of the 4-week intervention period and 3 months after Study profile.
stroke. These consisted of the ARAT 21 (4-week), Frenchay Arm Test, 20 Motricity Index, 19 Star Cancellation Test, 24 pain scales, 22, 23 disability, and global health status (Nottingham E-ADL Index 28 ; Nottingham Health Profile) 29 (3 months), Oxford Handicap Scale, 30 and participant views regarding sNMES. The stroke unit staff was not informed of participants' randomization groups. Outcome assessments were undertaken by 2 research nurses who were blinded to each participant's treatment allocation.
Statistical Methods and Sample Size
Using ARAT 21 scores from previous studies 31, 32 and allowing for 10% attrition, it was calculated that a total sample size of 168 subjects was needed to give an 80% power of detecting a clinically significant difference of 8 points (0.4 standard deviations). An intention to treat analysis was undertaken. Comparative analyses were made using the Mann-Whitney U test. For categorical data, a 2 test was used. Significance level was set at Pϭ0.05.
Ethical Approval and Data Storage
Ethical approval was obtained and data stored in accordance with the Data Protection Act.
Results
During the recruitment period (January 1, 2002 to February 29, 2004) , 1627 patients were admitted with a diagnosis of possible stroke. One hundred seventy-six patients participated in the study (Figure) . The main reasons for exclusion to study entry were no upper limb deficit (28%), residence outside the study area (19%), not within 10 days of stroke onset (12%), and significant receptive dysphasia (9%) ( Table 1) .
The median time from stroke to randomization was 5 days (interquartile range [IQR], 4 to 7) for the intervention group and 4 days (IQR, 3 to 7) for the control group. Groups were well matched for age, gender, stroke subtype, severity, and initial upper limb impairment (Table 2 ). More control subjects reported prestroke pain, and had a visuospatial deficit on clinical testing, but these differences were not significant.
The median total ARAT 21 score was 55.5 in the control group and 50 in the intervention group at 3 months (Pϭ0.068) ( Table 3 ). For other measures of upper limb function and impairment (grasp and gross subsections of the ARAT, 21 Frenchay Arm Test, 20 and the arm subsection of the Motricity Index, 19 the control group achieved statistically significantly higher scores than the intervention group. A greater proportion of participants failed the Star Cancellation Test 24 in the intervention group but this difference was not statistically significant. The prevalence of upper limb pain 22, 23 was similar between groups (45% control and 46% intervention). There were no differences in disability and global health status between groups. There were no statistically significant differences between groups at 4 weeks ( Table 4) .
As it has been suggested that sNMES may be more beneficial in stroke patients with milder upper limb impairment, 33 1 preplanned subgroup analysis was undertaken to 
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examine outcomes according to initial upper limb function (ARATϾ0 versus ARATϭ0) ( Table 5 ). No differences were seen between intervention and control groups for those with some upper limb function (ARATϾ0) at baseline. For those with no arm function at baseline (ARATϭ0), there were statistically significant differences for the grasp and gross subsections of the ARAT 21 and arm Motricity Index 19 in favor of the controls at 3 months but not at 1 month. Participants received 73% (IQR, 53.95 to 90) of intended sNMES. This was similar between groups (73% intervention, 72% control). At the 3-month assessment, 71% of the intervention group and 20% of the control group were able to correctly identify which stimulator (ie, active or sham) they had received. sNMES was well tolerated. The course was discontinued early for 5 (3 intervention and 2 control) participants at their request. In the intervention group, 18% attributed upper limb pain to the stimulator, compared with 1% of the control group.
Discussion
A 4-week program of sNMES to the shoulder did not improve upper limb function when initiated within 10 days of stroke onset. There was no difference in arm function between groups in terms of the primary outcome measure, Action Research Arm Test at 3 months. However, a number of secondary outcomes (upper limb impairment, other measures of arm function) were unexpectedly better in the control group 3 months after stroke, although this did not translate into differences in activities of daily living. There were no differences between randomization groups at 4 weeks.
Previous studies have suggested that sNMES helps to reduce or prevent shoulder subluxation, reduce pain, and improve muscle strength. 7, 12 It has been unclear whether this translates into an improvement in arm function. 7, 13, 14, 33 It is unlikely that we have failed to detect a significant treatment benefit. The study design was robust with adequate statistical power, and is the largest study of upper limb sNMES after acute stroke to date. Participants were typical stroke patients treated on stroke units and, there- fore, results are generalizable to this population. Previous studies recruited patients who were often younger and from neurorehabilitation settings.
It is thought that early intervention offers the greatest opportunity to improve recovery. 34, 35 We recruited participants early after stroke but found no benefit. Previous studies predominantly recruited participants months or even years after stroke and therefore may have treated the late complications of stroke rather than influenced recovery. 15, 33, 36 We applied sNMES to the shoulder as models of upper limb recovery suggest that proximal precede distal changes. 37 The regime has been shown to be beneficial in previous studies 13, 31 and is widely accepted in clinical practice. Unlike most previous studies we measured the amount of sNMES received. Both groups received less treatment than prescribed and it is conceivable that participants in the intervention group received suboptimal sNMES, although this was not significantly different from the control group. This may explain why we have not detected a treatment effect.
A strength of this study was the sham stimulator used by the placebo group. Only 5 previous randomized controlled trials have used sham treatment. 14,36,38 -40 As the active stimulator produced visible shoulder movement, complete blinding was not possible. The staff was not informed of participants' randomization groups but may have been aware by their own observations. The amount of upper limb rehabilitation received during the intervention period was not measured. If the intervention group received less, this may have been because of muscle fatigue or pain, or because therapists were reluctant to interrupt sNMES sessions for those with an active stimulator.
Although there is evidence that sNMES is beneficial in improving joint alignment (ie, reducing or preventing subluxation) and reducing spasticity, 6,7 we did not measure these outcomes. Subluxation is difficult to define, 41 and its measurement is unreliable and often of no clinical significance. 12 There is no validated measure of upper limb spasticity other than at the elbow. 42 We were surprised to find significant differences in some secondary outcomes at 3 months in favor of the control group. Secondary analysis suggested that these differences were most marked in subjects with severe initial upper limb weakness. The effect was seen after the sNMES had been discontinued ie, after 4 weeks. It is possible that sNMES interfered with motor re-learning processes, influencing and impeding upper limb recovery after the treatment period. Previous experimental models have suggested that very early constraint therapy and early overuse after cerebral ischemia in rodents may be harmful 43, 44 but the clinical relevance of this finding is not known. The negative effect of sNMES to the upper limb was seen only in those with initial severe impairment. Hypotheses to explain this include:
1. sNMES impedes recovery by producing abnormal afferent stimulation and inhibiting plasticity in a group who are not receiving any other afferent stimulation to the upper limb. It is possible that artificial stimulation proximally interferes with later distal recovery through maladaptive plasticity. 2. The movement produced at the shoulder may have resulted in early over-use of the affected arm. 3. Those with severe impairment may have been less aware of the stimulation and therefore less likely to report adverse events or be aware if the stimulator was wrongly delivered. 4. Overstimulation may have produced tiredness and shoulder subluxation (neither of these effects were measured). 5. As the stimulator produced movement of the shoulder, it is possible that participants used their affected arm less while it was being given, ie, the stimulator promoted learned non-use of this arm.
Those involved in the application of upper limb sNMES after stroke should be aware of its potential negative consequences, and of the lack of evidence to support its routine clinical use. If upper limb sNMES is to be used after stroke, a clearer understanding of its effects on recovery is vital, and further research should consider whether there is benefit for specific patient groups.
